Form D · Biotechnology
Pardes Biosciences, Inc
Carlsbad, CA · CIK 0001842257
Offering snapshot reported Feb 3, 2021 · SEC filing
- Reported sold
- $51.6M Offering amount: $51.6M
- Investors reported
- 36 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 19, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 3, 2021 | Initial | $51,614,997 | No comparison | 36 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-388339
Source: Form D, filed Feb 3, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lee Arnold | Executive |
| Mark Aueurbach | Director |
| Heidi Henson | Executive |
| Elizabeth Lacy | Executive |
| J. Jay Lobell | Director |
| Uri A. Loptain | Director, Executive |
| James B. Tananbaum | Director |
| Michael D. Varney | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2173 Salk Ave., Suite 250 Pmb #052
Carlsbad, CA, 92008
Carlsbad, CA, 92008